null Marie-Josée Brouillette, MD

Scientist, RI-MUHC , 5252 de Maisonneuve

Infectious Diseases and Immunity in Global Health Program

Centre for Outcomes Research and Evaluation

Associate Professor, Department of Psychiatry, Faculty of Medicine and Health Sciences, McGill University



cognition in HIV • depression • rasch analysis

Research Focus

My research focuses on the psychiatric care of patients infected with HIV and those undergoing treatment for hepatitis C. These studies are concerned with regulation of cognition and mood. My main study in the area of HIV involves characterizing 900 HIV+ individuals across Canada who will be followed for 2.5 years to elucidate factors that contribute to the development of cognitive decline, with interventional trials being conducted in selected subgroups of individuals. Other projects include (1) documenting changes in cognition in HIV+ individuals at risk of cognitive decline over 1 year; (2) improving cognition in HIV+ individuals through a personalized change in antiretroviral medication informed by analysis of cerebrospinal fluid; and (3) developing a computerized tool that can measure cognitive ability in a clinical setting. All these studies involve interdisciplinary collaborations (neurology, neuropsychology, epidemiology, HIV clinicians and community groups) and aim to develop innovative solutions that can be applied in the clinic.

Selected Publications

Click on Pubmed to see my current publications list

  • A better screening tool for HIV-associated neurocognitive disorders: is it what clinicians need? Brouillette MJ, Mayo N, Fellows LK, Lebedeva E, Higgins J, Overton ET, Ances BM, Koski L. AIDS. 2015 May 15;29(8):895-902. PMID: 25291105.

  • The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial. Lebouché B, Jenabian MA, Singer J, Graziani GM, Engler K, Trottier B, Thomas R, Brouillette MJ, Routy JP. Trials. 2014 Oct 7;15:390. PMID: 25293882.

  • Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial. Klein MB, Lee T, Brouillette MJ, Sheehan NL, Walmsley S, Wong DK, Conway B, Hull M, Cooper C, Haidar S, Vezina S, Annable L, Young S, Zubyk W, Singer J. HIV Clin Trials. 2014 Jul-Aug;15(4):161-75. PMID: 25143025.

  • Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Mind Exchange Working Group. Clin Infect Dis. 2013 Apr;56(7):1004-17. PMID: 23175555.

  • Computerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment(*). Koski L, Brouillette MJ, Lalonde R, Hello B, Wong E, Tsuchida A, Fellows L. HIV Med. 2011 Sep;12(8):472-80.PMID: 21395965.